Abstract
Malignant hypertension (MHT) is the most severe form of hypertension which is clinically defined as the presence of high blood pressure in association with bilateral retinal haemorrhages and/or exudates, with or without papilloedema. The aim of this review article is to discuss whether MHT is a problem which is truly becoming a rarity, or is it simply a problem with underdiagnosis. Despite the improvements in the general management of hypertension, we have no strong evidence of a declining incidence of MHT. In contrast, this disorder may appear to become even more common worldwide taking into account the growing hypertensive population in the developing countries. Although the diagnostic criteria of MHT appear to be simple and straightforward, the prompt diagnose of MHT may be difficult in substantial proportion of patients who often present with clinical symptoms only at a late stage of irreversible target organ changes. Furthermore, MHT and the accompanying ocular changes may gradually resolve making retrospective diagnosis problematic, whilst persistent target organ damage can drive the development of complications and have a negative prognosis in these patients. Clearly, MHT should not yet be forgotten nor ignored by clinicians.
Keywords: Maligant hypertension, hypertensive encephalopathy, renal failure, Malignant Hypertension, bilateral retinal haemorrhages, papilloe-dema, blood pressure, stroke, myocardial infarction, Takayasu's arteritis, aortoarteritis, fibromuscular dysplasia, West Birmingham MHT, retinopathy/kwd, >, fibrinoid necrosis, uraemic syndrome, scleroderma, choroidopathy, optic neuropathy, retinitis, arteriovenous nipping, papilledema, fundus hypertonicus, vasculopathies, retinal artery occlusion, left ventricular hypertrophy, renal dysfunction, angiotensin-aldesteron system, proteinuria, hypokalaemia, brain oedema, neurological syndromes, PROGNOSIS
Current Vascular Pharmacology
Title: Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Volume: 8 Issue: 6
Author(s): Alena Shantsila, Eduard Shantsila and Gregory Y.H. Lip
Affiliation:
Keywords: Maligant hypertension, hypertensive encephalopathy, renal failure, Malignant Hypertension, bilateral retinal haemorrhages, papilloe-dema, blood pressure, stroke, myocardial infarction, Takayasu's arteritis, aortoarteritis, fibromuscular dysplasia, West Birmingham MHT, retinopathy/kwd, >, fibrinoid necrosis, uraemic syndrome, scleroderma, choroidopathy, optic neuropathy, retinitis, arteriovenous nipping, papilledema, fundus hypertonicus, vasculopathies, retinal artery occlusion, left ventricular hypertrophy, renal dysfunction, angiotensin-aldesteron system, proteinuria, hypokalaemia, brain oedema, neurological syndromes, PROGNOSIS
Abstract: Malignant hypertension (MHT) is the most severe form of hypertension which is clinically defined as the presence of high blood pressure in association with bilateral retinal haemorrhages and/or exudates, with or without papilloedema. The aim of this review article is to discuss whether MHT is a problem which is truly becoming a rarity, or is it simply a problem with underdiagnosis. Despite the improvements in the general management of hypertension, we have no strong evidence of a declining incidence of MHT. In contrast, this disorder may appear to become even more common worldwide taking into account the growing hypertensive population in the developing countries. Although the diagnostic criteria of MHT appear to be simple and straightforward, the prompt diagnose of MHT may be difficult in substantial proportion of patients who often present with clinical symptoms only at a late stage of irreversible target organ changes. Furthermore, MHT and the accompanying ocular changes may gradually resolve making retrospective diagnosis problematic, whilst persistent target organ damage can drive the development of complications and have a negative prognosis in these patients. Clearly, MHT should not yet be forgotten nor ignored by clinicians.
Export Options
About this article
Cite this article as:
Shantsila Alena, Shantsila Eduard and Y.H. Lip Gregory, Malignant Hypertension: A Rare Problem or is it Underdiagnosed?, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563834
DOI https://dx.doi.org/10.2174/157016110793563834 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Microalbuminuria In Primary Hypertension
Current Hypertension Reviews Increased Neutrophil-to-lymphocyte Ratios are Associated with Greater Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Current Neurovascular Research Anti-Hypertensive
Current Bioactive Compounds N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Investigation of Drug Interaction Potentials and Binding Modes on Direct Renin Inhibitors: A Computational Modeling Studies
Letters in Drug Design & Discovery Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Structure – Activity Relationships of PDE5 Inhibitors (Supporting Material)
Current Medicinal Chemistry Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews Progress in the Mechanism and Clinical Application of Cilostazol
Current Topics in Medicinal Chemistry Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry Protective Effects of Terpenes on the Cardiovascular System: Current Advances and Future Perspectives
Current Medicinal Chemistry Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Current Vascular Pharmacology Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report
Current Drug Safety COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region
Current Diabetes Reviews